Medical, Interventional, and Surgical Treatment Strategies for Atrial Fibrillation

被引:3
作者
Willems, Stephan [1 ,3 ,4 ,5 ]
Gunawardene, Melanie A. [1 ,3 ]
Eickholt, Christian [1 ,3 ]
Hartmann, Jens [1 ,3 ]
Schmoeckel, Michael [2 ]
Schaeffer, Benjamin [1 ,3 ]
机构
[1] Asklepios Hosp St Georg, Dept Cardiol & Internal Intens Care Med, Hamburg, Germany
[2] Asklepios Hosp St Georg, Ctr Cardiac & Vasc Med, Dept Cardiac Surg, Hamburg, Germany
[3] Asklepios Prores, Hamburg, Germany
[4] German Ctr Cardiovasc Res DZHK, Partner Site Hamburg Kiel Lubeck, Berlin, Germany
[5] AFNET, Munster, Germany
来源
DEUTSCHES ARZTEBLATT INTERNATIONAL | 2022年 / 119卷 / 1-2期
关键词
CATHETER ABLATION; RHYTHM CONTROL; METAANALYSIS; MANAGEMENT; WARFARIN; STROKE;
D O I
10.3238/arztebl.m2022.0002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Atrial fibrillation is the most common type of cardiac arrhythmia; the lifetime risk for a 55-year-old person to develop atrial fibrillation is 37%. In recent years, there have been various distinct changes in the clinical management of AF. Methods: This review is based on a selective search for literature on the treatment of AF and the prevention of thromboembolic complications. The updated guideline of the European Society of Cardiology (ESC) for the diagnosis and treatment of AF was also taken into consideration. Results: The main components of AF management are the comprehensive treatment of risk factors and concomitant diseases, as well as the prevention of thromboembolic complications, usually with non-vitamin-K-dependent oral anticoagulants or vitamin K antagonists, according to individual risk stratification. Beyond this, either rate or rhythm control are viable treatment concepts. Symptomatic patients in whom reversible causes have been ruled out should be offered rhythm-control therapy early in their course. In patients with risk factors and/or heart failure, an early rhythm control strategy has been found to be beneficial. As antiarrhythmic drugs often prove to be ineffective over the long term, catheter ablation is now becoming increasingly important in AF management. Conclusion: The clinical management of atrial fibrillation consists of a multimodal approach with risk stratification, lifestyle modification, prevention of thromboembolism, and, if possible, early rhythm control therapy.
引用
收藏
页码:11 / +
页数:13
相关论文
共 40 条
[1]   Effect of Weight Reduction and Cardiometabolic Risk Factor Management on Symptom Burden and Severity in Patients With Atrial Fibrillation A Randomized Clinical Trial [J].
Abed, Hany S. ;
Wittert, Gary A. ;
Leong, Darryl P. ;
Shirazi, Masoumeh G. ;
Bahrami, Bobak ;
Middeldorp, Melissa E. ;
Lorimer, Michelle F. ;
Lau, Dennis H. ;
Antic, Nicholas A. ;
Brooks, Anthony G. ;
Abhayaratna, Walter P. ;
Kalman, Jonathan M. ;
Sanders, Prashanthan .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (19) :2050-2060
[2]   Catheter Ablation Versus Medical Therapy for Atrial Fibrillation A Systematic Review and Meta-Analysis of Randomized Controlled Trials [J].
Asad, Zain Ul Abideen ;
Yousif, Ali ;
Khan, Muhammad Shahzeb ;
Al-Khatib, Sana M. ;
Stavrakis, Stavros .
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2019, 12 (09)
[3]   The Society of Thoracic Surgeons 2017 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation [J].
Badhwar, Vinay ;
Rankin, J. Scott ;
Damiano, Ralph J., Jr. ;
Gillinov, A. Marc ;
Bakaeen, Faisal G. ;
Edgerton, James R. ;
Philpott, Jonathan M. ;
McCarthy, Patrick M. ;
Bolling, Steven F. ;
Roberts, Harold G. ;
Thourani, Vinod H. ;
Suri, Rakesh M. ;
Shemin, Richard J. ;
Firestone, Scott ;
Ad, Niv .
ANNALS OF THORACIC SURGERY, 2017, 103 (01) :329-341
[4]   Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation The CAPTAF Randomized Clinical Trial [J].
Blomstrom-Lundqvist, Carina ;
Gizurarson, Sigfus ;
Schwieler, Jonas ;
Jensen, Steen M. ;
Bergfeldt, Lennart ;
Kenneback, Goran ;
Rubulis, Aigars ;
Malmborg, Helena ;
Raatikainen, Pekka ;
Lonnerholm, Stefan ;
Hoglund, Niklas ;
Mortsell, David .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (11) :1059-1068
[5]   Cryoablation vs. radiofrequency ablation for treatment of paroxysmal atrial fibrillation: a systematic review and meta-analysis [J].
Chen, Yi-He ;
Lu, Zhao-Yang ;
Yin-Xiang ;
Hou, Jian-Wen ;
Wang, Qian ;
Lin, Hui ;
Li, Yi-Gang .
EUROPACE, 2017, 19 (05) :784-794
[6]  
Dagres N, EUR HEART J, V42, P373
[7]  
Dan GA, 2018, EUROPACE, V20, P731, DOI 10.1093/europace/eux373
[8]   Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial [J].
Di Biase, Luigi ;
Mohanty, Prasant ;
Mohanty, Sanghamitra ;
Santangeli, Pasquale ;
Trivedi, Chintan ;
Lakkireddy, Dhanunjaya ;
Reddy, Madhu ;
Jais, Pierre ;
Themistoclakis, Sakis ;
Dello Russo, Antonio ;
Casella, Michela ;
Pelargonio, Gemma ;
Narducci, Maria Lucia ;
Schweikert, Robert ;
Neuzil, Petr ;
Sanchez, Javier ;
Horton, Rodney ;
Beheiry, Salwa ;
Hongo, Richard ;
Hao, Steven ;
Rossillo, Antonio ;
Forleo, Giovanni ;
Tondo, Claudio ;
Burkhardt, J. David ;
Haissaguerre, Michel ;
Natale, Andrea .
CIRCULATION, 2016, 133 (17) :1637-1644
[9]   MORTALITY AND MORBIDITY IN PATIENTS RECEIVING ENCAINIDE, FLECAINIDE, OR PLACEBO - THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL [J].
ECHT, DS ;
LIEBSON, PR ;
MITCHELL, LB ;
PETERS, RW ;
OBIASMANNO, D ;
BARKER, AH ;
ARENSBERG, D ;
BAKER, A ;
FRIEDMAN, L ;
GREENE, HL ;
HUTHER, ML ;
RICHARDSON, DW .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (12) :781-788
[10]   Dabigatran versus warfarin in patients with mechanical heart valves: reply [J].
Eikelboom, J. W. ;
Brueckmann, M. ;
van de Werf, F. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (03) :426-426